JG
PTGX icon

Joel Greenblatt’s Protagonist Therapeutics PTGX Stock Holding History

Joel Greenblatt’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Sell
18,663
-2,492
-12% -$260K 0.01% 1109
2026
Q1 		$2.23M Sell
21,155
-440
-2% -$39K 0.01% 1076
2025
Q4 		$1.89M Sell
21,595
-603
-3% -$49.4K 0.01% 1059
2025
Q3 		$1.47M Sell
22,198
-15,089
-40% -$858K 0.01% 1086
2025
Q2 		$2.06M Buy
37,287
+14,215
+62% +$682K 0.01% 923
2025
Q1 		$1.12M Buy
+23,072
New +$967K 0.01% 972
2021
Q3 		– Sell
-4,793
Closed -$215K – 1102
2021
Q2 		$215K Buy
+4,793
New +$158K 0.01% 937

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Joel Greenblatt's PTGX Position: Q2 2026 in Review

Joel Greenblatt reduced its Protagonist Therapeutics (PTGX) stake by 12% in Q2 2026, selling an estimated $260K and leaving 18,663 shares worth $2.29M. The position accounts for 0.01% of the portfolio, ranked #1109.

Joel Greenblatt first reported a position in PTGX in Q2 2021 and has held it in 7 quarters since. 341 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Joel Greenblatt held 18,663 shares of Protagonist Therapeutics worth $2.29M as of Q2 2026.
  • Joel Greenblatt sold 2,492 Protagonist Therapeutics shares in Q2 2026, an estimated $260K.
  • Protagonist Therapeutics made up 0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1109 holding.
  • Joel Greenblatt first reported a position in Protagonist Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • 341 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.